Hailey Murphy
Payments from drug & device makers
Across 256 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$899
- AbbVie$835
- Bayer$358
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$347
- Amgen$261
- Takeda Pharmaceuticals U.S.A., Inc.$202
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,639100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $899 |
| AbbVie | 41 | $835 |
| Bayer | 21 | $358 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $347 |
| Amgen | 17 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $202 |
| Daiichi Sankyo Inc. | 7 | $199 |
| Lilly USA, LLC | 12 | $196 |
| Ardelyx, Inc. | 11 | $185 |
| Pfizer | 9 | $154 |
| Astellas Pharma US Inc | 9 | $137 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| Lundbeck LLC | 6 | $98 |
| Novo Nordisk | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Axsome Therapeutics, Inc. | 4 | $76 |
| Novartis | 3 | $71 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| AstraZeneca | 2 | $33 |
| Sumitomo Pharma America, Inc. | 1 | $31 |
| Boehringer Ingelheim | 2 | $27 |
| Corcept Therapeutics | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Sanofi | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$229
- INJECTAFER$115
How this compares
$4,639 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $80,090 |
| OzempicSemaglutide | 71 | $71,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $32,838 |
| LinzessLinaclotide | 47 | $32,490 |
| JardianceEmpagliflozin | 28 | $22,579 |
| EliquisApixaban | 26 | $18,096 |
| TrulicityDulaglutide | 17 | $17,973 |
| JanuviaSitagliptin Phosphate | 21 | $12,121 |
| FarxigaDapagliflozin Propanediol | 11 | $8,360 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $7,828 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,271 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $6,126 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 109 | $3,714 |
| Clonidine | 31 | $2,985 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $196 | $98,06384 claims |
| Novo NordiskOzempic | $89 | $71,62271 claims |
| GSKTrelegy Ellipta | $899 | $32,83844 claims |
| AbbVieLinzess | $835 | $32,49047 claims |
| Boehringer IngelheimJardiance | $27 | $22,57928 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $33 | $22,31552 claims |
| PfizerEliquis | $154 | $18,09626 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $202 | $7,27119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Baker
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.